Moreover, only ENTA is aiming for an all-oral (no RNAi) functional cure, as far as I know.
ASMB’s 2-DAA attempt at a functional cure (#msg-159327881) was doomed insofar as ABI-70831 was a weak agent, something noted by ENTA’s CEO, Jay Luly, on several occasions.